Business Association Chemistry Pharma Life Sciences
Mercosur: The Wrong Time to Say No

Dossiers - Customs policy and free trade

Mercosur: The Wrong Time to Say No

25.06.2026

Switzerland derives its prosperity from international markets. That is why the National Council’s decision of 17 June 2026 to reject the free trade agreement between the EFTA states and Mercosur, comprising Argentina, Brazil, Paraguay and Uruguay, is so difficult to understand. While the European Union is already improving market access for its businesses, Switzerland is letting an opportunity slip away and allowing valuable time to pass.

A contradiction in plain sight

More than half of Swiss merchandise exports come from the chemical, pharmaceutical and life sciences industries.

All of Switzerland’s productivity growth between 2013 and 2023 can be attributed to these sectors.

Around 80,000 people work directly in these industries, while a further 285,000 jobs in other sectors depend on them either directly or indirectly.

These figures do not describe a niche sector. They represent a substantial share of Swiss prosperity. They also represent industries that rely on attractive framework conditions and reliable access to international markets if they are to continue generating value and growth. Switzerland as a business location is under increasing pressure, and its attractiveness can no longer be taken for granted.

Against this backdrop, it is surprising that the National Council has chosen to reject a free trade agreement that would have improved access to a market of around 270 million people.

Global competition for investment, talent and emerging technologies is intensifying. Many countries are securing new market opportunities for their businesses. The majority of the National Council believes Switzerland should forgo them.

Competitors will not wait

The EFTA states and the Mercosur countries concluded negotiations in 2025. The agreement has been signed.

The European Union has already moved ahead. Since May 2026, it has been provisionally applying its own Mercosur agreement.

Swiss companies are therefore competing in the same markets as European rivals that already enjoy more favourable conditions.

That has real consequences. Exporters feel the impact through pricing, tenders, investment decisions and market share.

Every additional month of delay gives competitors a further advantage.

Far from a niche market

Mercosur is often portrayed in political debate as a distant region of limited economic significance. The facts suggest otherwise.

Argentina, Brazil, Paraguay and Uruguay together form a market of around 270 million people. In 2025, scienceindustries member companies exported goods worth CHF 3.16 billion to these four countries.

Brazil ranked as the twelfth most important export market for our industries, while Argentina ranked twenty-sixth.

Among all trading partners with which Switzerland does not yet have a free trade agreement, Mercosur already ranks second. There is nothing marginal about this market.

Free trade creates opportunities

Free trade agreements secure market access. They strengthen the protection of intellectual property. They provide greater legal certainty for investment.

For the chemical, pharmaceutical and life sciences industries, tariffs are also a very practical consideration. Depending on the country and product category, Mercosur tariffs can reach as high as 35 per cent.

The agreement would provide tariff relief worth around CHF 50 million for products from these industries.

This would strengthen the competitiveness of Swiss companies in an important market while also benefiting customers and other purchasers across the Mercosur countries. Such framework conditions are also part of the puzzle in maintaining Switzerland’s long-term attractiveness as a business location.

Sustainability must deliver results

Criticism of the agreement has focused primarily on environmental and sustainability issues. These concerns deserve to be taken seriously and discussed openly. The Swiss chemical, pharmaceutical and life sciences industries are firmly committed to sustainable development in all three of its dimensions: economic, environmental and social. Open and rules-based trade makes an important contribution to this objective by creating prosperity, fostering innovation and opening up opportunities for development. Where shortcomings arise, they can be addressed constructively through the Joint Committee established under the

Free Trade Agreement, including by exchanging best practices and identifying practical solutions. Free Trade Agreements should facilitate trade, not be rendered ineffective through additional compliance requirements. Overburdening agreements with ever more conditions risks making them so complex that businesses – particularly SMEs – no longer make use of them. Nor should Free Trade Agreements become vehicles for the extraterritorial application of domestic laws with a neo-colonial undertone. Such an approach would not empower smaller producers in partner countries; instead, it would push them out of the market because they lack the financial and technical resources to comply with increasingly burdensome requirements.

Mercosur will not disappear if Switzerland rejects this agreement. Nor will trade. The European Union is already implementing its agreement, and other countries are expanding their economic ties with the region. Those who want to shape developments and exert influence need a seat at the table.

Waiting is not a strategy

The European Union has made its decision. Argentina, Brazil, Paraguay and Uruguay have made theirs.

Only Switzerland is still debating.

Mercosur will not wait for Switzerland. Neither will the global economy.

The Council of States now has the opportunity to clear the way for the agreement.

Switzerland can either allow its businesses to compete in growth markets or stand by and watch others seize the opportunities.


Close

Newsletter subscription

scienceindustries News
Standpoints
Point